The Study of the Decade Results are In!

 

The first randomized clinical trial to evaluate UVC disinfection utilized Tru-D and validated that advanced terminal disinfection leads to a safer patient environment. The CDC-funded Benefits of Enhanced Terminal Room-Disinfection (BETR-D) study found that adding Tru-D enhanced no-touch disinfection has been shown to reduce the relative risk of colonization and infection of major superbugs by a cumulative 30% among patients admitted to the same room when 93% compliance of standard disinfection protocols occurred. Individual hospital results may vary.

Tru-D_2018-Device_noBkg

Tru-D’s patented method of measuring reflective dose shown to reduce the risk of infections

The first randomized clinical trial to evaluate UVC disinfection utilized Tru-D and validated that advanced terminal disinfection leads to a safer patient environment. The CDC-funded Benefits of Enhanced Terminal Room-Disinfection (BETR-D) study found that adding Tru-D enhanced no-touch disinfection has been shown to reduce the relative risk of colonization and infection of major superbugs by a cumulative 30% among patients admitted to the same room when 93% compliance of standard disinfection protocols occurred. Individual hospital results may vary.

These reduction rates, validated through the first and only randomized clinical trial of its kind, differentiate Tru-D from all other devices on the market.

Read the Abstract
new-case-study-image-hallway

The BETR-D Abstract Presented

The long awaited BETR-D abstract, Benefits of Enhanced Terminal Room-Disinfection (BETR-D)and a Duke Medicine news article have been released.

 

 

See the Latest from Duke